Most read articles by the same author(s)
- Alessio Aghemo, Giovanna Lunghi, Roberto Ravasio, Erminio Torresani, Matteo Dionisi, Davide Paolini, Massimo Colombo, Cost analysis of residual viremia detected by two real-time PCR assays for response-guided (dual or triple) therapy of HCV genotype 1 infection: Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia , Global and Regional Health Technology Assessment: Vol. 4 No. 1 (2017): January-December 2017
- Roberto Ravasio, Economic Impact of Therapeutic Choices: The Case of Incretins: Economic Impact of Therapeutic Choices: The Case of Incretins , Global and Regional Health Technology Assessment: Vol. 1 No. 2 (2014): July-December 2014
- Andrea Ardizzoni, Ilaria Attili, Federico Cappuzzo, Andrea De Giglio, Filippo De Marinis, Maristella Giammaruco, Cesare Gridelli, Vito Ladisa, Paolo Maione, Silvia Novello, Francesco Passiglia, Federica Maiocchi, Edoardo Sanna, Roberto Ravasio, The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus , Global and Regional Health Technology Assessment: Vol. 13 No. 1 (2026): January-December 2026




